A normal blood pressure is under 120/80, and if you're being treated for high blood pressure, the current US guideline sets the goal for most adults at under 130/80. Those numbers come from a 2025 American Heart Association and American College of Cardiology guideline that formally replaced the 2017 version, and the lower treatment goal still rests heavily on a 2015 trial that found treating to an even tighter systolic target cut heart attacks, strokes, and deaths in people who already had elevated cardiovascular risk.
| Category | Systolic | Diastolic |
|---|---|---|
| Normal | Under 120 | and under 80 |
| Elevated | 120–129 | and under 80 |
| Stage 1 hypertension | 130–139 | or 80–89 |
| Stage 2 hypertension | 140 or higher | or 90 or higher |
| Treatment goal, most treated adults | Under 130 | and under 80 |
What number counts as high blood pressure now?
The categories above haven't changed since 2017: a reading counts as the higher category if either number — systolic or diastolic — lands there, even if the other number is normal. The 2025 guideline kept this framework rather than redrawing the lines again; what it updated was the evidence behind the treatment targets and the tools clinicians use to estimate a given patient's cardiovascular risk. A single elevated reading in a clinic, taken once, isn't a diagnosis on its own — guidelines call for an average of more than one properly measured reading, often confirmed at home, before any category is assigned.
If you're already being treated, what's the actual target?
For most adults being treated for high blood pressure, the 2025 guideline's goal is under 130/80, and it encourages clinicians to aim for a systolic number under 120 when a patient tolerates it well. For people with stage 1 hypertension and a lower estimated 10-year cardiovascular risk, the guideline recommends a 3-to-6-month trial of lifestyle changes before starting medication, as long as blood pressure stays under 130/80 during that window. Adults with diabetes or chronic kidney disease share the same under-130/80 goal, but the guideline recommends starting medication earlier for them — at a reading of 130/80 or higher, rather than waiting through a lifestyle-only trial.
Why is the target lower than it used to be?
The specific number — 130/80 instead of the older 140/90 — traces back largely to a single trial. Researchers randomly assigned 9,361 adults with a systolic pressure of 130 or higher and an elevated cardiovascular risk, but without diabetes, to a target under 120 or a target under 140. After a median of 3.26 years, the trial stopped early: the group treated to the lower target had a composite rate of heart attack, other acute coronary events, stroke, heart failure, or cardiovascular death of 1.65% a year, versus 2.19% a year in the standard-target group — a relative reduction large enough, and a difference detected soon enough, that continuing the trial unchanged was no longer considered appropriate. All-cause mortality was also lower in the intensively treated group. The tradeoff ran the other way on side effects: the lower-target group had more episodes of low blood pressure, fainting, electrolyte problems, and acute kidney injury, though not more injury-causing falls.
That's a strong result, but it's a result for the population the trial actually enrolled — people already at meaningfully elevated cardiovascular risk, and never anyone with diabetes. It doesn't tell you what the right number is for a 50-year-old with no other risk factors, which is part of why the guideline still allows room for an individualized target rather than a single rule for everyone.
Does the target change after a certain age?
Not uniformly — and the guideline bodies don't fully agree with each other here. The AHA/ACC guideline extends the under-130-systolic goal to adults 65 and older who live independently and can walk on their own, based substantially on the same trial above, but it steps back from a fixed number for people with heavy comorbidity or a limited life expectancy, leaving that to clinical judgment and the patient's own preferences. A separate guideline from the American College of Physicians and the American Academy of Family Physicians takes a different position for adults 60 and older generally: it recommends starting treatment at a systolic pressure of 150 or higher, with a goal of under 150 — a less strict number than the AHA/ACC's — reserving a tighter under-140 goal for people with a history of stroke or a transient ischemic attack. Neither position is "wrong"; they reflect different weighing of the same evidence on benefit versus treatment burden, which is exactly why the number that applies to you is a conversation with your own clinician rather than something you can look up once and apply forever.
What the research says
The SPRINT trial randomly assigned 9,361 adults with elevated cardiovascular risk and no diabetes to a systolic blood-pressure target under 120 or under 140, and found that the lower target reduced a composite of major cardiovascular events and separately reduced all-cause mortality enough that the trial was stopped early, at the cost of more treatment-related adverse events.¹ The finding applies specifically to people who resemble the trial's population — already at elevated cardiovascular risk, without diabetes — and the researchers themselves note the tradeoff in side effects as part of the result, not an asterisk on it.
The 2025 AHA/ACC guideline, which formally retires the 2017 version, sets a treatment goal under 130/80 for most adults, encourages an under-120 systolic number when it's well tolerated, and extends the same goal to adults with diabetes or chronic kidney disease while starting their treatment earlier.² The American College of Physicians and American Academy of Family Physicians guideline reaches a different number for adults 60 and older broadly — under 150 systolic, strong recommendation — based on its own systematic review of the same category of evidence, illustrating that "the target" isn't a single settled fact across every professional body.³
What you can do this week
- Get more than one reading before trusting it. A single clinic reading can run high just from the visit itself; guidelines lean on repeated readings, often confirmed with a home monitor, before treating any one number as the real one.
- Compare your number to the table above, then ask your own clinician which target applies to you. Age, diabetes, kidney function, and overall cardiovascular risk all change the right goal — there's no single number that's correct for everyone over 50.
- If weight is one of the factors behind your numbers, that's worth raising with a clinician. Pallas prescribes compounded semaglutide and tirzepatide when a US-licensed clinician decides it's appropriate.
